CapyFin

Loading...

CapyFin Real-time Earnings Reports.

Products

Earnings
API

Get in Touch

Contact Us
X (Twitter)
LinkedIn

Resources

Privacy Policy
Terms of Service
Sign Up
Sign In

© 2025 CapyFin. All rights reserved.

Disclaimer: This platform provides information and recommendations for educational purposes only and is not a substitute for professional financial advice. Our content covers a range of investment classes, including stocks and cryptocurrencies, and we do not guarantee the completeness, accuracy, reliability, or suitability of this information, which may include data from third-party services and content generated by artificial intelligence (AI). Investing in stocks, cryptocurrencies, and other financial instruments involves risks, including the potential loss of principal. Users should independently verify all information and seek advice from qualified professionals tailored to their individual financial situations and investment objectives. Our content and services are provided "as is" without any warranties, express or implied. We are not liable for any losses or damages arising from the use of our services. This disclaimer is subject to change; users are advised to review it periodically. Usage of our services constitutes acceptance of these terms.

🇺🇸 NASDAQ:TXMD

Overview Earnings Dividends

May 10, 2024

•

Mar 31, 2024

TherapeuticsMD Q1 2024 Earnings Report

Reported financial results for the first quarter ended March 31, 2024.

Key Takeaways

TherapeuticsMD, Inc. reported financial results for the first quarter ended March 31, 2024, focusing on pharmaceutical royalties collection after transitioning from a women's healthcare company in December 2022.

TherapeuticsMD is now primarily focused on collecting royalties from its licensees.

The company is no longer engaged in research and development or commercial operations.

TherapeuticsMD is evaluating strategic alternatives, including potential acquisition, merger, or sale of assets.

The company's future performance depends on the success of its licensees in commercializing licensed products.

Total Revenue

$313K

Previous year: $416K

-24.8%

EPS

-$0.07

Previous year: -$0.24

-70.8%

Gross Profit

$180K

Previous year: $389K

-53.7%

Cash and Equivalents

$4.34M

Previous year: $49.3M

-91.2%

Free Cash Flow

$11K

Total Assets

$42.1M

Previous year: $59.6M

-29.4%

TherapeuticsMD

TherapeuticsMD

Company Overview

Full financial data and analysis

View TherapeuticsMD